Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cerebral metabolic effects of intravenous glycine in healthy human subjects.
Neumeister A, Carson R, Henry S, Planeta-Wilson B, Binneman B, Maguire RP, Luckenbaugh DA, D'Souza C, Krystal JH, Frost JJ. Neumeister A, et al. Among authors: binneman b. J Clin Psychopharmacol. 2006 Dec;26(6):595-9. doi: 10.1097/01.jcp.0000245558.14284.aa. J Clin Psychopharmacol. 2006. PMID: 17110816 Clinical Trial.
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder.
Simen A, Whitlock M, Qiu R, Miceli J, Zumpano L, Du Metz M, Dua P, Binneman B. Simen A, et al. Among authors: binneman b. J Clin Psychopharmacol. 2019 Jan/Feb;39(1):20-27. doi: 10.1097/JCP.0000000000000997. J Clin Psychopharmacol. 2019. PMID: 30531477 Clinical Trial.
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B. Miyoshi I, et al. Among authors: binneman b. Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816. Int J Clin Pharmacol Ther. 2013. PMID: 24131736 Clinical Trial.
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Landen JW, et al. Among authors: binneman b. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067341 Free PMC article.
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.
Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM. Landen JW, et al. Among authors: binneman b. Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067345 Free PMC article.
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, Mancuso J, Miceli J, Bell J. Fullerton T, et al. Among authors: binneman b. Alzheimers Res Ther. 2018 Apr 5;10(1):38. doi: 10.1186/s13195-018-0368-9. Alzheimers Res Ther. 2018. PMID: 29622037 Free PMC article. Clinical Trial.
Comments on "Presidential address: advocacy as leadership".
Clary C, Loebel A, Lombardo I, Alphs L, Binneman B, Vanderburg D, Warrington L, Parsons B, Fogel I, Herman B, Roberts H, Templeton H, Hughes D, Chappell P, Feltner D, Tobias K, Watsky E, Ramey T, Rappard F. Clary C, et al. Among authors: binneman b. Am J Psychiatry. 2007 Feb;164(2):346; author reply 346. doi: 10.1176/appi.ajp.164.2.346. Am J Psychiatry. 2007. PMID: 17267802 No abstract available.
A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index.
Schubert JJ, Veronese M, Fryer TD, Manavaki R, Kitzbichler MG, Nettis MA, Mondelli V, Pariante CM, Bullmore ET; NIMA Consortium; Turkheimer FE. Schubert JJ, et al. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul;6(7):716-724. doi: 10.1016/j.bpsc.2020.12.017. Epub 2021 Jan 28. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021. PMID: 33515765 Free PMC article.
18 results